Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

YY-20394 Combined With GEMOX in the Treatment of Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma With a Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

NCT04500561 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04500561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04500561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
YY-20394 Combined With GEMOX in the Treatment of Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma With a Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 20, 2020
Completion date
December 1, 2021
Enrollment
28 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma